HOME >> MEDICINE >> NEWS
Aventis Pasteur statement on HVTN 501 decision

Aventis Pasteur remains committed to the continued development of its ALVAC vector as a preventive AIDS vaccine. The knowledge gleaned from HIV Vaccine Trials Network (HVTN) 203 will be useful in moving future studies forward both in the U.S. and internationally.

There is no known correlate of protection for HIV vaccines. HVTN 501 was designed to determine possible correlates in addition to looking at efficacy of a prime-boost combination, using an ALVAC-HIV (vCP1452) prime and a gp120 boost. Because a correlate of protection analysis would not be able to be obtained from HVTN 501, that trial will not proceed. The decision, made by the NIAID and HVTN, was based on a review of data from HVTN 203 and is supported by the company.

However, the opportunity to see if the prime-boost, using ALVAC-HIV and gp120, is efficacious remains imminent. A phase III trial to be undertaken in Thailand with the Thai government and Walter Reed Army Institute of Research is planned to begin later this year. The Thai trial and HVTN 501 had different objectives. The Thai study is a straightforward community-based trial with efficacy as its outcome. The company will cooperate fully with the trial.

The NIAID and HVTN remain fully committed to several other trials using ALVAC-HIV (vCP1452) and the company intends to support them. HVTN (HIVNET) 026 looks at the safety and immunogenicity of ALVAC-HIV (vCP1452) and gp120 MN in populations outside of the U.S. HVTN 039 is studying whether a higher dose level of ALVAC-HIV (vCP1452) results in an enhanced HIV-specific immune response in vaccinees. HVTN 042 will seek to determine if there is a benefit to using a different boost, in this case lipopeptides and is in collaboration with the Agence Nationale de Recherche Sur de Sida (ANRS).

Importantly, all of these trials will help guide the companys R and D efforts in this area as well as build a continuing record of safety for these approaches. AL
'"/>

Contact: Robert Sebbag/Beth Waters
33-60-817-2183
Cooney Waters Group, Inc.
25-Feb-2002


Page: 1 2

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Millennium, Aventis Pharma form novel alliance
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. NHLBI statement on oral contraceptive study
6. NIH panel issues State-of-the-Science statement on end-of-life care
7. Doctors statement in Mayo Clinic Proceedings reveals dark side of low-carb diets
8. American Heart Association consensus statement
9. NIA statement on IOM testosterone report
10. American Psychiatric Association issues statement on compulsive shopping
11. New statement proposes ways to stop deadly drug errors among heart, stroke patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aventis Pasteur statement HVTN decision

(Date:4/1/2015)... WI (PRWEB) April 01, 2015 When ... dryness occur, waiting days or weeks for an appointment ... Historically same and next day appointments haven’t been possible ... area, Forefront Dermatology’s offices have noticed demand for this ... , “We realize how important relief or answers to ...
(Date:4/1/2015)... GA (PRWEB) April 01, 2015 ... Medicine Practice, Pediatric Emergency Medicine Practice, and Hospital ... has partnered with AgileMD to provide the content ... , in a mobile application format available on ... , “Our collaboration with AgileMD to develop mobile ...
(Date:4/1/2015)... 01, 2015 On May 1, 2015, the ... annual Educational Institute in Albany, New York . This ... in nursing and feature an address by Helen R. Connors, ... Professor, University of Kansas School of Nursing and Center for ... being sponsored by the Excelsior College School of Nursing, ...
(Date:4/1/2015)... Washington, D.C. (PRWEB) April 01, 2015 It ... eaten solely for breakfast but now found wrapped around other ... products. Bacon has been called meat candy, the gateway meat ... as a cultural icon, the North American Meat Institute (NAMI) ... featuring a video tour of a bacon processing plant ...
(Date:4/1/2015)... 01, 2015 Natural fertility experts from ... attend the world’s first Integrative Fertility Symposium ( https://ifsymposium.com/ ... Centre (SFU Downtown Campus), 515 West Hastings Street, Vancouver ... Sunday, May 3rd, 3:00 pm to 5:00 pm at ... first of its kind in the world to bring ...
Breaking Medicine News(10 mins):Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 2Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 3Health News:New Ultimate Guide to Bacon Video Provides Inside Look at How Bacon is Made 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 3
(Date:4/1/2015)...  Salix Pharmaceuticals, Ltd. ("Salix"), a wholly owned ... VRX ) (TSX:VRX), today announced that it will ... amount of its 6.00% Senior Notes due 2021, ... pursuant to two redemptions. On May 1, 2015, ... the Notes, and on May 4, 2015, Salix ...
(Date:4/1/2015)... 1, 2015   AMC Health , a leading ... in monitored care that are transforming chronic care and ... Conference. The conference will be held at McCormick ... 12 through 16. In addition to demonstrating its partnerships ... Health will share innovations that transform the way healthcare ...
(Date:4/1/2015)... N.J. , April 1, 2015  Janssen Therapeutics, ... recipients of funding from a special request for applications ... Drugs Living with HIV and/or Hepatitis C." ... each will receive a one-year charitable contribution to enhance ... drugs living with HIV and/or hepatitis C. ...
Breaking Medicine Technology:Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 2Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 2AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 4Janssen Therapeutics Announces Support for Organizations Focused on Improving Care and Treatment for People Who Inject Drugs Living with HIV and/or Hepatitis C 2Janssen Therapeutics Announces Support for Organizations Focused on Improving Care and Treatment for People Who Inject Drugs Living with HIV and/or Hepatitis C 3Janssen Therapeutics Announces Support for Organizations Focused on Improving Care and Treatment for People Who Inject Drugs Living with HIV and/or Hepatitis C 4
Cached News: